Major Growth & Investment at Pace® Life Sciences

Pace® Life Sciences, a CRDMO, has experienced significant growth through recent acquisitions of analytical labs, substantially increasing their testing capacity and scientific expertise. Looking ahead to 2025, Pace® is undertaking key expansions at their Salem, NH, site to include sterile fill-finish capabilities for clinical trial manufacturing and at their Oakdale, MN, facility to double their biopharmaceutical analytical services. With a growing network of locations across major US pharmaceutical hubs, Pace® aims to enhance customer experience through consistent quality and timely delivery. The company anticipates continued growth through both organic initiatives and further acquisitions, supported by private equity investment.

Watch this video and learn more about:

• The company's most recent acquisitions.
• Sterile fill-finish capacity coming during Q3 of 2025.
• A headquarters expansion slated for 2025 for biopharmaceutical analytical services.